You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAlmotriptan
Accession NumberDB00918  (APRD00169)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionAlmotriptan is a triptan drug for the treatment of migraine headaches. Almotriptan is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and stopping the release of certain natural substances that cause pain, nausea, and other symptoms of migraine. Almotriptan does not prevent migraine attacks.
Structure
Thumb
Synonyms
1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine
External Identifiers
  • LAS 31416
  • LAS-31416
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Almotriptantablet12.5 mgoralPro Doc Limitee2014-06-10Not applicableCanada
Almotriptan Malatetablet, coated12.5 mg/1oralPatriot Pharmaceuticals, LLC2015-07-07Not applicableUs
Almotriptan Malatetablet, coated6.25 mg/1oralPatriot Pharmaceuticals, LLC2015-07-07Not applicableUs
Axerttablet, coated12.5 mg/1oralPhysicians Total Care, Inc.2006-02-09Not applicableUs
Axerttablet, coated12.5 mg/1oralJanssen Pharmaceuticals, Inc.2001-05-07Not applicableUs
Axerttablet, coated6.25 mg/1oralJanssen Pharmaceuticals, Inc.2001-05-07Not applicableUs
Axert 12.5mgtablet12.5 mgoralMcneil Consumer Healthcare Division Of Johnson & Johnson Inc2003-12-08Not applicableCanada
Axert 6.25mgtablet6.25 mgoralMcneil Consumer Healthcare Division Of Johnson & Johnson Inc2003-12-08Not applicableCanada
Mylan-almotriptantablet6.25 mgoralMylan Pharmaceuticals Ulc2013-07-22Not applicableCanada
Mylan-almotriptantablet12.5 mgoralMylan Pharmaceuticals Ulc2013-07-22Not applicableCanada
PMS-almotriptantablet12.5 mgoralPharmascience IncNot applicableNot applicableCanada
Sandoz Almotriptantablet12.5 mgoralSandoz Canada Incorporated2013-07-22Not applicableCanada
Teva-almotriptantablet12.5 mgoralTeva Canada Limited2014-12-12Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Almotriptantablet, film coated12.5 mg/1oralAjanta Pharma Limited2015-10-07Not applicableUs
Almotriptantablet, film coated6.25 mg/1oralAjanta Pharma Limited2015-10-07Not applicableUs
Almotriptan Malatetablet, film coated6.25 mg/1oralTeva Pharmaceuticals USA Inc2015-07-07Not applicableUs
Almotriptan Malatetablet, film coated12.5 mg/1oralTeva Pharmaceuticals USA Inc2015-07-07Not applicableUs
Almotriptan Malatetablet, film coated6.25 mg/1oralMylan Pharmaceuticals Inc.2015-11-10Not applicableUs
Almotriptan Malatetablet, film coated12.5 mg/1oralMylan Pharmaceuticals Inc.2015-11-10Not applicableUs
Apo-almotriptantablet6.25 mgoralApotex Inc2013-12-24Not applicableCanada
Apo-almotriptantablet12.5 mgoralApotex Inc2013-10-22Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlmogranNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Almotriptan malate
181183-52-8
ThumbNot applicableDBSALT001204
Categories
UNII1O4XL5SN61
CAS number154323-57-6
WeightAverage: 335.464
Monoisotopic: 335.166747749
Chemical FormulaC17H25N3O2S
InChI KeyInChIKey=WKEMJKQOLOHJLZ-UHFFFAOYSA-N
InChI
InChI=1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3
IUPAC Name
dimethyl(2-{5-[(pyrrolidine-1-sulfonyl)methyl]-1H-indol-3-yl}ethyl)amine
SMILES
CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tryptamines and derivatives. These are compounds containing the tryptamine backbone, which is structurally characterized by an indole ring subsituted at the 3-position by an ethanamine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIndoles and derivatives
Sub ClassTryptamines and derivatives
Direct ParentTryptamines and derivatives
Alternative Parents
Substituents
  • Tryptamine
  • Indole
  • Aralkylamine
  • Benzenoid
  • Substituted pyrrole
  • Heteroaromatic compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Pyrrolidine
  • Pyrrole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of acute migraine headache in adults
PharmacodynamicsAlmotriptan is a selective 5-hydroxytryptamine receptor subtype agonist indicated for the acute treatment of migraine attacks with or without aura in adults. Almotriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Almotriptan is an agonist for a vascular 5-hydroxytryptamine receptor subtype (probably a member of the 5-HT1D family) having only a weak affinity for 5-HT1A, 5-HT5A, and 5-HT7 receptors and no significant affinity or pharmacological activity at 5-HT2, 5-HT3 or 5-HT4 receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Almotriptan also activates 5-HT1 receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Almotriptan in humans.
Mechanism of actionAlmotriptan binds with high affinity to human 5-HT1B and 5-HT1D receptors leading to cranial blood vessel constriction.
Related Articles
AbsorptionNot Available
Volume of distribution
  • 180 to 200 L
Protein binding35%
Metabolism
SubstrateEnzymesProduct
Almotriptan
N-desmethylalmotriptanDetails
Almotriptan
2-{5-[(pyrrolidine-1-sulfonyl)methyl]-1H-indol-3-yl}acetic acidDetails
Almotriptan
2-{5-[(pyrrolidine-1-sulfonyl)methyl]-1H-indol-3-yl}ethan-1-olDetails
Almotriptan
1-[({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methane)sulfonyl]pyrrolidin-2-olDetails
Route of eliminationAlmotriptan is eliminated primarily by renal excretion (about 75% of the oral dose), with approximately 40% of an administered dose excreted unchanged in urine. Approximately 13% of the administered dose is excreted via feces, both unchanged and metabolized.
Half life3-4 hours
Clearance
  • 57 L/h [healthy]
  • 34.2 L/h [moderate renal impairment (creatinine clearance between 31 and 71 mL/min)]
  • 9.8 L/h [severe renal impairment (creatinine clearance between 10 and 30 mL/min)]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3
Gene symbol: GNB3
UniProt: P16520
rs5443 Not AvailableT AlleleBetter response to drug treatment17361120
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9781
Caco-2 permeable-0.7421
P-glycoprotein substrateSubstrate0.5636
P-glycoprotein inhibitor INon-inhibitor0.8282
P-glycoprotein inhibitor IINon-inhibitor0.8679
Renal organic cation transporterNon-inhibitor0.553
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.6292
CYP450 1A2 substrateNon-inhibitor0.605
CYP450 2C9 inhibitorNon-inhibitor0.8089
CYP450 2D6 inhibitorNon-inhibitor0.6273
CYP450 2C19 inhibitorNon-inhibitor0.8581
CYP450 3A4 inhibitorNon-inhibitor0.8929
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8486
Ames testNon AMES toxic0.6532
CarcinogenicityNon-carcinogens0.8588
BiodegradationNot ready biodegradable0.9508
Rat acute toxicity2.5976 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5255
hERG inhibition (predictor II)Non-inhibitor0.6008
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Ortho mcneil janssen pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Tablet, coatedoral12.5 mg/1
Tablet, coatedoral6.25 mg/1
Tablet, film coatedoral12.5 mg/1
Tablet, film coatedoral6.25 mg/1
Tabletoral12.5 mg
Tabletoral6.25 mg
Prices
Unit descriptionCostUnit
Axert 12 12.5 mg tablet Box300.14USD box
Axert 6 6.25 mg tablet Box150.05USD box
Axert 12.5 mg tablet24.05USD tablet
Axert 6.25 mg tablet24.05USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2120028 No1999-03-232013-07-19Canada
US5565447 Yes1995-11-072015-11-07Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP1.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.121 mg/mLALOGPS
logP2.04ALOGPS
logP1.52ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)17.14ChemAxon
pKa (Strongest Basic)9.55ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area56.41 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity94.52 m3·mol-1ChemAxon
Polarizability37.01 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Ramasubramanian Sridharan, Vandanapu Purushotham, Kori Algooram, Nitin Pradhan, “Crystalline forms of almotriptan and processes for their preparation.” U.S. Patent US20070112055, issued May 17, 2007.

US20070112055
General ReferencesNot Available
External Links
ATC CodesN02CC05
AHFS Codes
  • 28:32.28
PDB EntriesNot Available
FDA labelDownload (778 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe metabolism of Almotriptan can be decreased when combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.
AbirateroneThe serum concentration of Almotriptan can be increased when it is combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Aceprometazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Acetophenazine.
AmiodaroneThe metabolism of Almotriptan can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Almotriptan is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Almotriptan.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Almotriptan.
AmperozideThe risk or severity of adverse effects can be increased when Almotriptan is combined with Amperozide.
AprepitantThe serum concentration of Almotriptan can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Almotriptan is combined with Aripiprazole.
ArmodafinilThe metabolism of Almotriptan can be decreased when combined with Armodafinil.
ArtemetherThe metabolism of Almotriptan can be decreased when combined with Artemether.
AsenapineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Asenapine.
AtazanavirThe serum concentration of Almotriptan can be increased when it is combined with Atazanavir.
AtomoxetineThe metabolism of Almotriptan can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Almotriptan is combined with Azaperone.
AzithromycinThe metabolism of Almotriptan can be decreased when combined with Azithromycin.
BenmoxinThe metabolism of Almotriptan can be decreased when combined with Benmoxin.
BetaxololThe metabolism of Almotriptan can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Almotriptan can be decreased when it is combined with Bexarotene.
BifeprunoxThe risk or severity of adverse effects can be increased when Almotriptan is combined with Bifeprunox.
BoceprevirThe serum concentration of Almotriptan can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Almotriptan can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Almotriptan can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Almotriptan is combined with Brexpiprazole.
BromocriptineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Bromocriptine.
BromocriptineBromocriptine may increase the vasoconstricting activities of Almotriptan.
BupropionThe metabolism of Almotriptan can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Almotriptan.
CabergolineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Cabergoline.
CabergolineCabergoline may increase the vasoconstricting activities of Almotriptan.
CaffeineThe metabolism of Almotriptan can be decreased when combined with Caffeine.
CarbamazepineThe metabolism of Almotriptan can be increased when combined with Carbamazepine.
CariprazineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Cariprazine.
CaroxazoneThe metabolism of Almotriptan can be decreased when combined with Caroxazone.
CelecoxibThe metabolism of Almotriptan can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Almotriptan can be increased when it is combined with Ceritinib.
ChloramphenicolThe metabolism of Almotriptan can be decreased when combined with Chloramphenicol.
ChloroquineThe metabolism of Almotriptan can be decreased when combined with Chloroquine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Chlorpromazine.
ChlorpromazineThe metabolism of Almotriptan can be decreased when combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Almotriptan is combined with Chlorprothixene.
CholecalciferolThe metabolism of Almotriptan can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Almotriptan can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Almotriptan can be decreased when combined with Cinacalcet.
CitalopramThe metabolism of Almotriptan can be decreased when combined with Citalopram.
CitalopramThe risk or severity of adverse effects can be increased when Almotriptan is combined with Citalopram.
ClarithromycinThe serum concentration of Almotriptan can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Almotriptan can be decreased when combined with Clemastine.
ClobazamThe metabolism of Almotriptan can be decreased when combined with Clobazam.
ClomipramineThe metabolism of Almotriptan can be decreased when combined with Clomipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Clomipramine.
ClopidogrelThe metabolism of Almotriptan can be decreased when combined with Clopidogrel.
ClotrimazoleThe metabolism of Almotriptan can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Clozapine.
ClozapineThe metabolism of Almotriptan can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Almotriptan can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Almotriptan can be decreased when combined with Cocaine.
ConivaptanThe serum concentration of Almotriptan can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Almotriptan can be decreased when combined with Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Cyamemazine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Cyclobenzaprine.
CyclosporineThe metabolism of Almotriptan can be decreased when combined with Cyclosporine.
Cyproterone acetateThe serum concentration of Almotriptan can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Almotriptan can be decreased when it is combined with Dabrafenib.
DapiprazoleThe risk or severity of adverse effects can be increased when Almotriptan is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Almotriptan.
DarifenacinThe metabolism of Almotriptan can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Almotriptan can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Almotriptan can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Almotriptan can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Almotriptan can be decreased when combined with Delavirdine.
DesipramineThe metabolism of Almotriptan can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Desipramine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Desvenlafaxine.
DexamethasoneThe serum concentration of Almotriptan can be decreased when it is combined with Dexamethasone.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Almotriptan.
DihydroergotamineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Dihydroergotamine.
DihydroergotamineDihydroergotamine may increase the vasoconstricting activities of Almotriptan.
DiltiazemThe metabolism of Almotriptan can be decreased when combined with Diltiazem.
DiphenhydramineThe metabolism of Almotriptan can be decreased when combined with Diphenhydramine.
DisulfiramThe metabolism of Almotriptan can be decreased when combined with Disulfiram.
DolasetronDolasetron may increase the serotonergic activities of Almotriptan.
DoxepinThe risk or severity of adverse effects can be increased when Almotriptan is combined with Doxepin.
DoxycyclineThe metabolism of Almotriptan can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Almotriptan can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Almotriptan is combined with Droperidol.
DroxidopaAlmotriptan may increase the hypertensive activities of Droxidopa.
DuloxetineThe metabolism of Almotriptan can be decreased when combined with Duloxetine.
DuloxetineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Duloxetine.
EfavirenzThe serum concentration of Almotriptan can be decreased when it is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Almotriptan.
EliglustatThe metabolism of Almotriptan can be decreased when combined with Eliglustat.
EnzalutamideThe serum concentration of Almotriptan can be decreased when it is combined with Enzalutamide.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Almotriptan is combined with Ergoloid mesylate.
Ergoloid mesylateErgoloid mesylate may increase the vasoconstricting activities of Almotriptan.
ErgonovineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Ergonovine.
ErgonovineErgonovine may increase the vasoconstricting activities of Almotriptan.
ErgotamineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Ergotamine.
ErgotamineErgotamine may increase the vasoconstricting activities of Almotriptan.
ErythromycinThe metabolism of Almotriptan can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Almotriptan is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Almotriptan can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Almotriptan can be decreased when combined with Esomeprazole.
EtravirineThe serum concentration of Almotriptan can be decreased when it is combined with Etravirine.
FelodipineThe metabolism of Almotriptan can be decreased when combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Fencamfamine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Almotriptan.
FluconazoleThe metabolism of Almotriptan can be decreased when combined with Fluconazole.
FluoxetineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Fluoxetine.
FluoxetineThe metabolism of Almotriptan can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Almotriptan is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Almotriptan is combined with Fluspirilene.
FluvoxamineThe metabolism of Almotriptan can be decreased when combined with Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Fluvoxamine.
FosamprenavirThe metabolism of Almotriptan can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Almotriptan can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Almotriptan can be increased when combined with Fosphenytoin.
FrovatriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Frovatriptan.
FurazolidoneThe metabolism of Almotriptan can be decreased when combined with Furazolidone.
Fusidic AcidThe serum concentration of Almotriptan can be increased when it is combined with Fusidic Acid.
GemfibrozilThe metabolism of Almotriptan can be decreased when combined with Gemfibrozil.
GranisetronGranisetron may increase the serotonergic activities of Almotriptan.
HaloperidolThe risk or severity of adverse effects can be increased when Almotriptan is combined with Haloperidol.
HaloperidolThe metabolism of Almotriptan can be decreased when combined with Haloperidol.
HydracarbazineThe metabolism of Almotriptan can be decreased when combined with Hydracarbazine.
IdelalisibThe serum concentration of Almotriptan can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Almotriptan is combined with Iloperidone.
ImatinibThe metabolism of Almotriptan can be decreased when combined with Imatinib.
ImipramineThe metabolism of Almotriptan can be decreased when combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Imipramine.
IndinavirThe metabolism of Almotriptan can be decreased when combined with Indinavir.
IproclozideThe metabolism of Almotriptan can be decreased when combined with Iproclozide.
IproniazidThe metabolism of Almotriptan can be decreased when combined with Iproniazid.
IrbesartanThe metabolism of Almotriptan can be decreased when combined with Irbesartan.
IsavuconazoniumThe metabolism of Almotriptan can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Almotriptan is combined with Isocarboxazid.
IsocarboxazidThe metabolism of Almotriptan can be decreased when combined with Isocarboxazid.
IsoniazidThe metabolism of Almotriptan can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Almotriptan can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Almotriptan can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Almotriptan can be increased when it is combined with Ivacaftor.
KetoconazoleThe metabolism of Almotriptan can be decreased when combined with Ketoconazole.
LapatinibThe metabolism of Almotriptan can be decreased when combined with Lapatinib.
LevomilnacipranThe risk or severity of adverse effects can be increased when Almotriptan is combined with Levomilnacipran.
LidocaineThe metabolism of Almotriptan can be decreased when combined with Lidocaine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Almotriptan.
LithiumThe risk or severity of adverse effects can be increased when Almotriptan is combined with Lithium.
LopinavirThe serum concentration of Almotriptan can be increased when it is combined with Lopinavir.
LorcaserinThe metabolism of Almotriptan can be decreased when combined with Lorcaserin.
LorcaserinThe risk or severity of adverse effects can be increased when Almotriptan is combined with Lorcaserin.
LosartanThe metabolism of Almotriptan can be decreased when combined with Losartan.
LovastatinThe metabolism of Almotriptan can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Loxapine.
LuliconazoleThe serum concentration of Almotriptan can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Almotriptan can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Almotriptan can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Almotriptan is combined with Lurasidone.
MaprotilineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Maprotiline.
MebanazineThe metabolism of Almotriptan can be decreased when combined with Mebanazine.
MelperoneThe risk or severity of adverse effects can be increased when Almotriptan is combined with Melperone.
MesoridazineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Mesoridazine.
MethadoneThe metabolism of Almotriptan can be decreased when combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Almotriptan is combined with Methadone.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Methotrimeprazine.
MethotrimeprazineThe metabolism of Almotriptan can be decreased when combined with Methotrimeprazine.
Methylene blueThe metabolism of Almotriptan can be decreased when combined with Methylene blue.
MetoclopramideThe risk or severity of adverse effects can be increased when Almotriptan is combined with Metoclopramide.
MetoprololThe metabolism of Almotriptan can be decreased when combined with Metoprolol.
MexiletineThe metabolism of Almotriptan can be decreased when combined with Mexiletine.
MifepristoneThe metabolism of Almotriptan can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Almotriptan is combined with Milnacipran.
MinaprineThe metabolism of Almotriptan can be decreased when combined with Minaprine.
MirabegronThe metabolism of Almotriptan can be decreased when combined with Mirabegron.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Almotriptan.
MitotaneThe serum concentration of Almotriptan can be decreased when it is combined with Mitotane.
MoclobemideThe risk or severity of adverse effects can be increased when Almotriptan is combined with Moclobemide.
MoclobemideThe metabolism of Almotriptan can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Almotriptan can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Almotriptan is combined with Molindone.
NafcillinThe serum concentration of Almotriptan can be decreased when it is combined with Nafcillin.
NaratriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Naratriptan.
NefazodoneThe serum concentration of Almotriptan can be increased when it is combined with Nefazodone.
NefazodoneThe risk or severity of adverse effects can be increased when Almotriptan is combined with Nefazodone.
NelfinavirThe metabolism of Almotriptan can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Almotriptan can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Almotriptan can be decreased when combined with Nevirapine.
NialamideThe metabolism of Almotriptan can be decreased when combined with Nialamide.
NicardipineThe metabolism of Almotriptan can be decreased when combined with Nicardipine.
NicotineThe metabolism of Almotriptan can be decreased when combined with Nicotine.
NilotinibThe metabolism of Almotriptan can be decreased when combined with Nilotinib.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Almotriptan.
OctamoxinThe metabolism of Almotriptan can be decreased when combined with Octamoxin.
OlanzapineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Olanzapine.
OlaparibThe metabolism of Almotriptan can be decreased when combined with Olaparib.
OmeprazoleThe metabolism of Almotriptan can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Almotriptan is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Almotriptan.
OsanetantThe risk or severity of adverse effects can be increased when Almotriptan is combined with Osanetant.
OsimertinibThe serum concentration of Almotriptan can be increased when it is combined with Osimertinib.
PalbociclibThe serum concentration of Almotriptan can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Almotriptan is combined with Paliperidone.
PalonosetronPalonosetron may increase the serotonergic activities of Almotriptan.
PanobinostatThe metabolism of Almotriptan can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Almotriptan can be decreased when combined with Pantoprazole.
PargylineThe metabolism of Almotriptan can be decreased when combined with Pargyline.
ParoxetineThe metabolism of Almotriptan can be decreased when combined with Paroxetine.
ParoxetineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Almotriptan can be decreased when it is combined with Peginterferon alfa-2b.
PentobarbitalThe metabolism of Almotriptan can be increased when combined with Pentobarbital.
PerospironeThe risk or severity of adverse effects can be increased when Almotriptan is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Almotriptan.
PhenelzineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Phenelzine.
PhenelzineThe metabolism of Almotriptan can be decreased when combined with Phenelzine.
PheniprazineThe metabolism of Almotriptan can be decreased when combined with Pheniprazine.
PhenobarbitalThe metabolism of Almotriptan can be increased when combined with Phenobarbital.
PhenoxypropazineThe metabolism of Almotriptan can be decreased when combined with Phenoxypropazine.
PhenytoinThe metabolism of Almotriptan can be increased when combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Almotriptan is combined with Pimozide.
PioglitazoneThe metabolism of Almotriptan can be decreased when combined with Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Almotriptan is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Pipotiazine.
PirlindoleThe metabolism of Almotriptan can be decreased when combined with Pirlindole.
PivhydrazineThe metabolism of Almotriptan can be decreased when combined with Pivhydrazine.
PosaconazoleThe serum concentration of Almotriptan can be increased when it is combined with Posaconazole.
PrimidoneThe metabolism of Almotriptan can be increased when combined with Primidone.
ProcarbazineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Procarbazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Promazine.
PromazineThe metabolism of Almotriptan can be decreased when combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Promethazine.
PropericiazineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Propericiazine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Almotriptan.
QuetiapineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Quetiapine.
QuinidineThe metabolism of Almotriptan can be decreased when combined with Quinidine.
QuinineThe metabolism of Almotriptan can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Almotriptan can be decreased when combined with Rabeprazole.
RanolazineThe metabolism of Almotriptan can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Rasagiline.
RasagilineThe metabolism of Almotriptan can be decreased when combined with Rasagiline.
RemoxiprideThe risk or severity of adverse effects can be increased when Almotriptan is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Reserpine.
RifabutinThe metabolism of Almotriptan can be increased when combined with Rifabutin.
RifampicinThe metabolism of Almotriptan can be increased when combined with Rifampicin.
RifapentineThe metabolism of Almotriptan can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Almotriptan is combined with Risperidone.
RitonavirThe serum concentration of Almotriptan can be increased when it is combined with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Rizatriptan.
RolapitantThe metabolism of Almotriptan can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Almotriptan can be decreased when combined with Ropinirole.
RosiglitazoneThe metabolism of Almotriptan can be decreased when combined with Rosiglitazone.
SafrazineThe metabolism of Almotriptan can be decreased when combined with Safrazine.
SaquinavirThe serum concentration of Almotriptan can be increased when it is combined with Saquinavir.
SecobarbitalThe metabolism of Almotriptan can be increased when combined with Secobarbital.
SelegilineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Selegiline.
SelegilineThe metabolism of Almotriptan can be decreased when combined with Selegiline.
SertindoleThe risk or severity of adverse effects can be increased when Almotriptan is combined with Sertindole.
SertralineThe metabolism of Almotriptan can be decreased when combined with Sertraline.
SertralineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Sertraline.
SildenafilThe metabolism of Almotriptan can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Almotriptan can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Almotriptan can be increased when it is combined with Simeprevir.
St. John's WortThe serum concentration of Almotriptan can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Almotriptan can be increased when it is combined with Stiripentol.
SulfamethoxazoleThe metabolism of Almotriptan can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleThe metabolism of Almotriptan can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Almotriptan is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Almotriptan.
TamoxifenThe metabolism of Almotriptan can be decreased when combined with Tamoxifen.
TapentadolThe risk or severity of adverse effects can be increased when Almotriptan is combined with Tapentadol.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Almotriptan.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Almotriptan is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Almotriptan can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Almotriptan can be increased when it is combined with Telithromycin.
TenofovirThe metabolism of Almotriptan can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Almotriptan can be decreased when combined with Terbinafine.
TeriflunomideThe serum concentration of Almotriptan can be decreased when it is combined with Teriflunomide.
TheophyllineThe metabolism of Almotriptan can be decreased when combined with Theophylline.
ThioproperazineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Thioproperazine.
ThioridazineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Thioridazine.
ThioridazineThe metabolism of Almotriptan can be decreased when combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Almotriptan is combined with Thiothixene.
TiclopidineThe metabolism of Almotriptan can be decreased when combined with Ticlopidine.
TipranavirThe metabolism of Almotriptan can be decreased when combined with Tipranavir.
TocilizumabThe serum concentration of Almotriptan can be decreased when it is combined with Tocilizumab.
ToloxatoneThe metabolism of Almotriptan can be decreased when combined with Toloxatone.
TopiramateThe metabolism of Almotriptan can be decreased when combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Almotriptan.
Trans-2-PhenylcyclopropylamineThe metabolism of Almotriptan can be decreased when combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Tranylcypromine.
TranylcypromineThe metabolism of Almotriptan can be decreased when combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Almotriptan.
TrifluoperazineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Triflupromazine.
TrimethoprimThe metabolism of Almotriptan can be decreased when combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Almotriptan.
VemurafenibThe serum concentration of Almotriptan can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Almotriptan can be decreased when combined with Venlafaxine.
VenlafaxineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Venlafaxine.
VerapamilThe metabolism of Almotriptan can be decreased when combined with Verapamil.
VilazodoneThe risk or severity of adverse effects can be increased when Almotriptan is combined with Vilazodone.
VoriconazoleThe metabolism of Almotriptan can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Vortioxetine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Almotriptan is combined with Ziprasidone.
ZiprasidoneThe metabolism of Almotriptan can be decreased when combined with Ziprasidone.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Almotriptan.
ZotepineThe risk or severity of adverse effects can be increased when Almotriptan is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Almotriptan is combined with Zuclopenthixol.
Food Interactions
  • Take without regard to meals.
  • The absorption is unaffected by food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R: Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol. 1999 Mar 5;368(2-3):259-68. [PubMed:10193663 ]
  2. Bou J, Domenech T, Puig J, Heredia A, Gras J, Fernandez-Forner D, Beleta J, Palacios JM: Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. Eur J Pharmacol. 2000 Dec 20;410(1):33-41. [PubMed:11134654 ]
  3. Gras J, Llupia J, Llenas J, Palacios JM: Safety profile of almotriptan, a new antimigraine agent. Effects on central nervous system, renal function and respiratory dynamics. Arzneimittelforschung. 2001 Sep;51(9):726-32. [PubMed:11642004 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R: Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol. 1999 Mar 5;368(2-3):259-68. [PubMed:10193663 ]
  2. Fleishaker JC, Sisson TA, Carel BJ, Azie NE: Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin Pharmacol Ther. 2000 May;67(5):498-503. [PubMed:10824628 ]
  3. van den Broek RW, MaassenVanDenBrink A, de Vries R, Bogers AJ, Stegmann AP, Avezaat CJ, Saxena PR: Pharmacological analysis of contractile effects of eletriptan and sumatriptan on human isolated blood vessels. Eur J Pharmacol. 2000 Oct 27;407(1-2):165-73. [PubMed:11050304 ]
  4. Knyihar-Csillik E, Tajti J, Csillik AE, Chadaide Z, Mihaly A, Vecsei L: Effects of eletriptan on the peptidergic innervation of the cerebral dura mater and trigeminal ganglion, and on the expression of c-fos and c-jun in the trigeminal complex of the rat in an experimental migraine model. Eur J Neurosci. 2000 Nov;12(11):3991-4002. [PubMed:11069595 ]
  5. Bou J, Domenech T, Puig J, Heredia A, Gras J, Fernandez-Forner D, Beleta J, Palacios JM: Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. Eur J Pharmacol. 2000 Dec 20;410(1):33-41. [PubMed:11134654 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Salva M, Jansat JM, Martinez-Tobed A, Palacios JM: Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11. [PubMed:12642466 ]
  3. McEnroe JD, Fleishaker JC: Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46. [PubMed:15762767 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. McEnroe JD, Fleishaker JC: Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46. [PubMed:15762767 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. McEnroe JD, Fleishaker JC: Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46. [PubMed:15762767 ]
  2. Gras J, Llenas J, Jansat JM, Jauregui J, Cabarrocas X, Palacios JM: Almotriptan, a new anti-migraine agent: a review. CNS Drug Rev. 2002 Fall;8(3):217-34. [PubMed:12353056 ]
  3. Salva M, Jansat JM, Martinez-Tobed A, Palacios JM: Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11. [PubMed:12642466 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Trimethylamine monooxygenase activity
Specific Function:
Involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. It N-oxygenates primary aliphatic alkylamines as well as secondary and tertiary amines. Plays an important role in the metabolism of trimethylamine (TMA), via the production of TMA N-oxide (TMAO). Is also able to perform S-oxidation when acting on sulfide compounds (PubMed:9224773).
Gene Name:
FMO3
Uniprot ID:
P31513
Molecular Weight:
60032.975 Da
References
  1. Salva M, Jansat JM, Martinez-Tobed A, Palacios JM: Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11. [PubMed:12642466 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Salva M, Jansat JM, Martinez-Tobed A, Palacios JM: Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11. [PubMed:12642466 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Salva M, Jansat JM, Martinez-Tobed A, Palacios JM: Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11. [PubMed:12642466 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Salva M, Jansat JM, Martinez-Tobed A, Palacios JM: Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11. [PubMed:12642466 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Salva M, Jansat JM, Martinez-Tobed A, Palacios JM: Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11. [PubMed:12642466 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2016 02:17